Effects of the ACE inhibitor quinapril on echocardiographic variables in horses with mitral valve insufficiency.
Twenty horses with mitral valve insufficiency, but without signs of congestive heart failure, and five horses without signs of heart disease were examined before and after medication with an angiotensin-converting enzyme (ACE) inhibitor. The examination included echocardiography assessment as well as heart catheterization. The echocardiographic examination included B-mode, M-mode, conventional and colour Doppler techniques. For 8 weeks, all horses were treated with Accupro 20 (active substance: Quinapril) at an oral dose rate of 120 mg/horse/day. A follow-up of the horses with mitral valve insufficiency after 8 weeks revealed a statistically significant increase in the stroke volume and the cardiac output as well as a decrease in regurgitation velocity time integral (VTI). The regurgitation blood velocity remained the same. The severity of mitral valve insufficiencies revealed a moderate improvement in five horses, from moderate to mild, after therapy. Significant changes of cardiac dimension (B-mode) and shortening fraction (M-mode) before and after treatment could not be observed. The owners' judgement of the horses' performance was that of a minor improvement. In the horses without clinical findings the results of examination before and after treatment remained the same.
Gehlen
H
H
Equine Clinic, School of Veterinary Medicine Hannover, Hannover, Germany. heidrun.gehlen@tiho-hannover.de
Vieht
J C
JC
Stadler
P
P
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000818:Animals; D006328:Cardiac Catheterization; D004452:Echocardiography / Q000662:veterinary; D005260:Female; D006734:Horse Diseases / Q000000981:diagnostic imaging / Q000188:drug therapy*; D006736:Horses; D008297:Male; D008944:Mitral Valve Insufficiency / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000662:veterinary*; D000077583:Quinapril; D044005:Tetrahydroisoquinolines / Q000627:therapeutic use*; D016896:Treatment Outcome
D000806:Angiotensin-Converting Enzyme Inhibitors; D044005:Tetrahydroisoquinolines; D000077583:Quinapril